[1]吴昊,段海明.人表皮生长因子受体2阳性和三阴性乳腺癌患者新辅助化疗后腋窝淋巴结病理学分析[J].新乡医学院学报,2024,(4):358-362.[doi:10.7683/xxyxyxb.2024.04.011]
　WU Hao,DUAN Haiming.Pathology of axillary lymph nodes after neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer patients[J].Journal of Xinxiang Medical University,2024,(4):358-362.[doi:10.7683/xxyxyxb.2024.04.011]
点击复制

人表皮生长因子受体2阳性和三阴性乳腺癌患者新辅助化疗后腋窝淋巴结病理学分析
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
期数:
2024年4
页码:
358-362
栏目:
临床研究
出版日期:
2024-04-05

文章信息/Info

Title:
Pathology of axillary lymph nodes after neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer patients
作者:
吴昊; 段海明
（西安国际医学中心医院甲乳外科，陕西　西安　710100）
Author(s):
WU Hao; DUAN Haiming
(Department of Thyroid and Breast Surgery,Xi′an International Medical Center Hospital,Xi′an 710100,Shaanxi Province,China)
关键词:
人表皮生长因子受体2阳性乳腺癌; 三阴性乳腺癌; 新辅助化疗; 腋窝淋巴结
Keywords:
human epidermal growth factor receptor 2 positive breast cancer; triple-negative breast cancer; neoadjuvant chemotherapy; axillary lymph node
分类号:
R737.9
DOI:
10.7683/xxyxyxb.2024.04.011
文献标志码:
A
摘要:
目的　探讨人表皮生长因子受体2（HER2）阳性和三阴性乳腺癌患者新辅助化疗后腋窝淋巴结病理学情况，并分析HER2阳性和三阴性乳腺癌患者新辅助化疗后腋窝淋巴结病理学阳性（ypN0）的影响因素。
方法　回顾性分析2019年9月至2022年1月西安国际医学中心医院收治的72例HER2阳性和三阴性乳腺癌患者的临床资料，其中HER2阳性乳腺癌患者35例，三阴性乳腺癌患者37例。根据患者新辅助化疗后腋窝淋巴结病理学分为ypN0组（n=41）和非ypN0组（n=31）。比较2组患者的绝经情况、病理类型、乳腺癌类型、新辅助化疗疗程、肿瘤最大直径、新辅助化疗前肿瘤分期、新辅助化疗前淋巴结分期、新辅助化疗后乳房影像学完全缓解（brCR）情况、新辅助化疗后淋巴结临床阴性（cN0）情况、新辅助化疗后原发肿瘤病理学完全缓解（pCR）情况，采用多因素logistic回归分析HER2阳性和三阴性乳腺癌患者新辅助化疗后ypN0的独立影响因素，分析新辅助化疗前淋巴结分期cN0、cN1（临床淋巴结阳性）患者新辅助化疗后ypN0情况。
结果　ypN0组与非ypN0组患者的绝经情况、病理类型、乳腺癌类型、新辅助化疗疗程、肿瘤最大直径比较差异无统计学意义（P>0.05）；ypN0组与非ypN0组患者新辅助化疗前肿瘤分期、淋巴结分期及新辅助化疗后原发肿瘤影像学检查显示brCR情况、淋巴结检查显示cN0情况、原发肿瘤pCR情况比较差异有统计学意义（P<0.05）。多因素logistic回归分析显示，新辅助化疗前淋巴结分期、新辅助化疗后淋巴结cN0、新辅助化疗后原发肿瘤pCR是HER2阳性和三阴性乳腺癌患者新辅助化疗后ypN0的独立影响因素（P<0.05）。14例新辅助化疗前淋巴结分期cN0患者，新辅助化疗后6例获得pCR、8例未获得pCR。获得pCR和未获得pCR患者的ypN0率分别为100%（6/6）、75%（6/8），获得pCR患者和未获得pCR患者的ypN0率比较差异无统计学意义（χ2=1.750，P=0.186）。33例新辅助化疗前淋巴结分期为cN1患者，新辅助化疗后10例获得pCR、23例未获得pCR。获得pCR和未获得pCR患者的ypN0率分别为100.00%（10/10）、39.13%（9/23），获得pCR患者的ypN0率高于未获得pCR患者（χ2=10.572，P=0.001）。
结论　HER2阳性和三阴性乳腺癌患者新辅助化疗前淋巴结分期、新辅助化疗后淋巴结cN0、新辅助化疗后原发肿瘤pCR与腋窝淋巴结病理学有关，新辅助化疗后pCR的cN0及部分cN1 的HER2阳性和三阴性乳腺癌患者腋窝转移风险低，可考虑腋窝降阶梯手术。
Abstract:
Objective　To investigate the pathology of axillary lymph nodes after neoadjuvant chemotherapy (NAC) for human epidermal growth factor receptor 2 (HER2) positive and triple-negative breast cancer and analyze the influencing factors of pathologically positive (ypN0) axillary lymph nodes.
Methods　The clinical data of 72 patients with HER2-positive and triple-negative breast cancer admitted to the Xi′an International Medical Center Hospital from September 2019 to January 2022 were retrospectively analyzed,including 35 patients with HER2-positive breast cancer and 37 patients with triple-negative breast cancer.According to the pathology of axillary lymph nodes after NAC,the patients were divided into the ypN0 group (n=41) and the non-ypN0 group (n=31).The menopausal status,pathological type,breast cancer type,NAC duration,maximum tumor diameter,tumor staging before NAC,lymph node staging before NAC,breast radiologic complete response (brCR) after NAC,clinically negative lymph node (cN0) after NAC,and pathologic complete response (pCR) of primary tumor after NAC were compared between the two groups.The independent factors influencing ypN0 after NAC in HER2-positive and triple-negative breast cancer patients were analyzed using the multivariate logistic regression,and the ypN0 status of patients with lymph node stages cN0 and cN1 before NAC was also analyzed.
Results　There were no significant differences in menopausal status,pathological type,breast cancer type,NAC duration and maximum tumor diameter between the ypN0 group and the non-ypN0 group (P>0.05).There were statistically significant differences between the ypN0 group and the non-ypN0 group in tumor staging before NAC,lymph node staging before NAC,brCR of primary tumor after NAC,cN0 after NAC,and pCR of primary tumor after NAC (P<0.05).The multivariate logistic regression analysis showed that lymph node staging before NAC,lymph node cN0 after NAC,and pCR of primary tumor after NAC were independent factors affecting ypN0 after NAC in HER2-positive and triple-negative breast cancer patients (P<0.05).Among the 14 cN0 patients before NAC,6 achieved pCR and 8 did not achieve pCR after NAC.The ypN0 rate between patients who achieved pCR ［100% (6/6)］ and patients who did not achieve pCR ［75% (6/8)］ after NAC had no significant difference (χ2=1.750,P=0.186).Among the 33 cN1 patients before NAC,10 achieved pCR and 23 did not achieve pCR after NAC.The ypN0 rate in patients with pCR after NAC ［100% (10/10)］ was higher than that in patients without pCR ［39.13% (9/23)］ (χ2=10.572,P=0.001).
Conclusion　For HER2-positive and triple-negative breast cancer patients,the lymph node staging before NAC,lymph node cN0 after NAC,and primary tumor pCR after NAC are related to the pathology of axillary lymph nodes.All cN0 patients and some cN1 patients with pCR after NAC have a low risk of axillary metastasis,and axillary de-escalation surgery can be considered.

参考文献/References:

［1］　MICHAELS E,WORTHINGTON R O,RUSIECKI J.Breast cancer:risk assessment,screening,and primary prevention［J］.Med Clin North Am,2023,107(2):271-284.
［2］　柴效科,卫翀羿,程晓成,等.激素受体阳性/人类表皮生长因子受体2阴性乳腺癌靶向治疗研究进展［J］.〖KG-\*4〗新乡医学院学报,2023,40(5):490-496.
CHAI X K,WEI C Y,CHENG X C,et al.Research progress on targeted therapy of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer［J］.J Xinxiang Med Univ,2023,40(5):490-496.
［3］　HARBECK N.〖KG-\*8〗Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer［J］.Breast,2022,62(Suppl 1):S12-S16.
［4］　ALDRICH J,CANNING M,BHAVE M.Monitoring of triple negative breast cancer after neoadjuvant chemotherapy［J］.〖KG-\*8〗Clin Breast Cancer,2023,23(8):832-834.
［5］　FENG W,HE Y,XU J,et al.A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer［J］.Anticancer Drugs,2022,33(1):e52-e60.
［6］　GROOT S D,LUGTENBERG R T,COHEN D,et al.Fasting mimic-king diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial［J］.Nat Commun,2020,11(1)〖KG-\*8〗:3083.
［7］　GIAMMARILE F,VIDAL-SICART S,PAEZ D,et al.Sentinel lymph node
Methods　in breast cancer［J］.Semin Nucl Med,2022,52(5):551-560.
［8］　中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017年版)［J］.〖KG-\*8〗中国癌症杂志,2017,27(9):695-759.
BREAST CANCER PROFESSIONAL COMMITTEE OF CHINESE ANTI-CANCER ASSOCIATION.Guidelines and specifications for diagnosis and treatment of breast cancer of China Anti-Cancer Association (2017 edition)［J］.China Oncol,2017,27(9):695-759.
［9］　FISHER C S.Neoadjuvant chemotherapy for breast cancer:the ultimate “spy”［J］.Ann Surg Oncol,2022,29(11):6508-6510.
［10］　崔茹婷,吕志栋,姚瑶,等.钙周期素结合蛋白对乳癌新辅助化疗效果的预测价值［J］.青岛大学学报(医学版),2022,58(5):714-719.
CUI R T,LV Z D,YAO Y,et al.Value of calcyclin-binding protein in predicting the efficacy of neoadjuvant chemotherapy for breast cancer［J］.J Qingdao Univ Med Sci,2022,58(5):714-719.
［11］　KATSURA C,OGUNMWONYI I,KANKAM H K,et al.Breast cancer:presentation,investigation and management［J］.Br J Hosp 〖HJ1.49mm〗Med (Lond),2022,83(2):1-7.
［12］　蔡凌翼,陈涛,张晓琳,等.基于基因组学视角的乳腺癌化疗耐药机制研究进展［J］.中华全科医学,2023,21(12):2005-2008,2073.
CAI L Y,CHEN T,ZHANG X L,et al.Advances in the study of chemotherapy resistance mechanisms in breast cancer based on genomics perspective［J］.Chin J Gen Pract,2023,21(12):2005-2008,2073.
［13］　HAQUE W,VERMA V,SCHWARTZ M R,et al.Neoadjuvant chemotherapy for metaplastic breast cancer:response rates,management,and outcomes［J］.Clin Breast Cancer,2022,22(5):e691-e699.
［14］　杨柳,张明坤,季福庆,等.HER-2阳性乳腺癌新辅助化疗疗效影响因素分析及相关预后模型的构建［J］.现代肿瘤医学,2023,31(11):2037-2041.
YANG L,ZHANG M K,JI F Q,et al.The analysis of the factors affecting pathological complete response of HER-2 positive breast cancer patients after neoadjuvant chemotherapy and the construction of related model［J］.〖KG-\*8〗J Mod Oncol,2023,31(11):2037-2041.
［15］　李芷凡,刘欣然,王子圆,等.ADC最大值联合激素受体及人表皮生长因子受体2预测乳腺癌新辅助化疗疗效［J］.磁共振成像,2023,14(10):71-77.
LI Z F,LIU X R,〖KG-\*8〗WANG Z Y,et al.Predicting the efficacy of neoadjuvant chemotherapy for breast cancer by combining hormone receptor and human epidermal growth factor receptor 2 with ADC maximum［J］.Chin J Magn Reson Imag,2023,14(10):71-77.
［16］　苏天放,范明,厉力华.基于纵向时间影像动态增强模式分析的乳腺癌新辅助化疗疗效预测［J］.中国生物医学工程学报,2023,42(2):139-147.
SU T F,FAN M,LI L H.〖KG-\*8〗Prediction of breast cancer neoadjuvant chemotherapy based on dynamic enhanced mode analysis of longitudinal time images［J］.Chin J Biomed Eng,2023,42(2):139-147.
［17］　SINGAPORE CANCER NETWORK BREAST CANCER WORKGROUP.Singapore cancer network (SCAN) guidelines for bisphosphonate use in the adjuvant breast cancer setting［J］.Ann Acad Med Singap,2015,44(10):368-378.
［18］　TYAGI N K,DHESY-THIND S.Clinical practice guidelines in breast cancer［J］.Curr Oncol,2018,25(Suppl 1):S151-S160.
［19］　樊庆达,丛斌斌,陈玉光,等.临床淋巴结阳性新辅助治疗后腋窝降阶处理的研究进展［J］.〖KG-\*8〗中国癌症杂志,2023,33(2):174-180.
FAN Q D,CONG B B,CHEN Y G,et al.Research progress of axillary de-escalation management after neoadjuvant chemotherapy for clinical lymph node positive patients［J］.China Oncol,2023,33(2):174-180.
［20］　BOUGHEY J C,SUMAN V J,MITTENDORF E A,et al.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer:the ACOSOG Z1071 (Alliance) clinical trial［J］.JAMA,2013,310(14):1455-1461.
［21］　VAN DER NOORDAA M,VAN DUIJNHOVEN F,CUIJPERS V,et al.Omitting sentinel lymph node biopsy after neoadjuvant systemic therapy in selected breast cancer patients with clinical node-negative disease［J］.Eur J Cancer,2018,92:S14.
［22］　BLUM MURPHY M,XIAO L,PATEL V R,et al.Pathological complete response in patients with esophageal cancer after the trimodality approach:the association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience［J］.Cancer,2017,123(21):4106-4113.

相似文献/References:

[1]路　娜,古吉敏,闵志波.肿瘤间质比在三阴性乳腺癌患者预后评估中的价值[J].新乡医学院学报,2017,34(12):1089.[doi:10.7683/xxyxyxb.2017.12.011]
　LU Na,GU Ji-min,MIN Zhi-bo.Value of tumor-stroma ratio in evaluating the prognosis of patients with triple-negative breast cancer[J].Journal of Xinxiang Medical University,2017,34(4):1089.[doi:10.7683/xxyxyxb.2017.12.011]
[2]刘　明,郭　满,张　浩,等.血管生成拟态及骨桥蛋白和基质金属蛋白酶2在三阴性乳腺癌组织中的表达及意义[J].新乡医学院学报,2019,36(4):345.[doi:10.7683/xxyxyxb.2019.04.011]
　LIU Ming,GUO Man,ZHANG Hao,et al.Expression and significance of vasculogenic mimicry，osteopontin and matrix metalloproteinase-2 in triple-negative breast cancer[J].Journal of Xinxiang Medical University,2019,36(4):345.[doi:10.7683/xxyxyxb.2019.04.011]
[3]郭　满,翟晓建,张　浩,等.p38蛋白激酶信号通路对骨桥蛋白介导的三阴性乳腺癌细胞自噬、凋亡活性的影响[J].新乡医学院学报,2018,35(12):1058.[doi:10.7683/xxyxyxb.2018.12.004]
　GUO Man,ZHAI Xiao-jian,ZHANG Hao,et al.Effect of p38 mitogen-activated protein kinase signaling pathway on autophagy and apoptosis activity of triple negative breast cancer cell mediated by osteopontin[J].Journal of Xinxiang Medical University,2018,35(4):1058.[doi:10.7683/xxyxyxb.2018.12.004]
[4]刘德总,杨颖涛.乳腺癌辅助治疗现状与展望[J].新乡医学院学报,2021,38(8):781.[doi:10.7683/xxyxyxb.2021.08.017]
[5]郭彬彬,郭　满,刘　明,等.扭曲蛋白、波形蛋白、血管生成拟态在三阴性乳腺癌组织中的表达及临床意义[J].新乡医学院学报,2021,38(5):436.[doi:10.7683/xxyxyxb.2021.05.008]
　GUO Binbin,GUO Man,LIU Ming,et al.Expression of Twist,vimentin and vasculogenic mimicry in triple-negative breast cancer tissues and its clinical significance[J].Journal of Xinxiang Medical University,2021,38(4):436.[doi:10.7683/xxyxyxb.2021.05.008]
[6]付朝红,刘丹娜,段方方,等.晚期三阴性乳腺癌核苷酸切除修复交叉互补基因1表达与化学治疗效果的关系[J].新乡医学院学报,2017,34(10):904.[doi:10.7683/xxyxyxb.2017.10.010]
　FU Chao-hong,LIU Dan-na,DUAN Fang-fang,et al.Relationship between excision repair cross complementing gene 1 expression and chemotherapeutic efficacy in patients with advanced triple-negative breast cancer[J].Journal of Xinxiang Medical University,2017,34(4):904.[doi:10.7683/xxyxyxb.2017.10.010]
[7]朱方园,邵营波,陈　琦,等.长链非编码RNA前列腺癌相关转录本7对三阴性乳腺癌MDA-MB-436细胞增殖、迁移及侵袭的影响[J].新乡医学院学报,2022,39(8):701.[doi:10.7683/xxyxyxb.2022.08.001]
　ZHU Fangyuan,SHAO Yingbo,CHEN Qi,et al.Effect of long non-coding RNA prostate cancer associated transcript 7 on proliferation,migration and invasion of triple-negative breast cancer MDA-MB-436 cells[J].Journal of Xinxiang Medical University,2022,39(4):701.[doi:10.7683/xxyxyxb.2022.08.001]

更新日期/Last Update: 2024-04-05